Ovid Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| For the Year Ended December 31,2023 | For the Year Ended December 31,2022 | |
|---|---|---|
| Net loss | $(52,338,959) | $(54,169,029) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | 702 | (42,187) |
| Comprehensive loss | $(52,338,257) | $(54,211,216) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.